A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...

Intravesical sequential BCG and electromotive mitomycin versus BCG alone in high risk non-muscle invasive bladder cancer. Results of a phase II study of pralatrexate in patients with ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

Noninvasive treatment options for NGB dysfunction include intermittent catheterization, Crede and Valsalva, indwelling catheterization, lifestyle changes/behavioral modification, and oral ...